Harnessing the therapeutic value of Tanshinone IIA: a breakthrough therapy in cardiovascular diseases
Frontiers in Pharmacology · 04.07.2025 · 16
DOI: 10.3389/fphar.2025.1620152 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.07.2025. Verfasst von Lanxiang Du und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traumatic Orthopedics, Ganzhou Traditional Chinese Medicine Hospital Affiliated to Jiangxi University of Chinese Medicine, Ganzhou, Chi…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province.
Abstract (Originalsprache)
Cardiovascular diseases (CVDs) have emerged as one of the leading causes of global mortality and health burden, with their prevalence and mortality rates demonstrating a persistent upward trend, thereby posing significant challenges to public health worldwide. Tanshinone IIA (Tan IIA), the principal lipophilic bioactive component isolated from Salvia miltiorrhiza Bunge , has gained substantial recognition in cardiovascular therapeutics. Accumulating evidence from recent investigations has demonstrated that Tan IIA exhibits multi-target pharmacological properties and modulates diverse signaling pathways in cardiovascular protection, positioning it as a promising candidate in natural product-based drug discovery. The therapeutic efficacy is mediated through multiple mechanisms, including but not limited to anti-atherosclerotic effects, lipid homeostasis regulation, anti-arrhythmic properties, myocardial functional enhancement, and hemodynamic stabilization. This comprehensive review systematically elucidates the molecular mechanisms and therapeutic targets underlying Tan IIA’s cardio-protective effects, particularly focusing on its anti-inflammatory, antioxidant, anti-atherosclerotic, and myocardial preservation properties. Furthermore, we critically evaluate its current clinical applications and propose potential directions for future research to optimize its therapeutic potential in cardiovascular medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Traumatic Orthopedics, Ganzhou Traditional Chinese Medicine Hospital Affiliated to Jiangxi University of Chinese Medicine, Ganzhou, China.
- Clinical Medical College, Jiangxi University of Chinese Medicine, Nanchang, China.
- Department of Medical Cardiology, Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province
Zitieren
APA
Du, L., Guan, C., Zhang, H., Jia, H., & Wan, Q. (2025). Harnessing the therapeutic value of Tanshinone IIA: a breakthrough therapy in cardiovascular diseases. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1620152
Vancouver
Du L, Guan C, Zhang H, Jia H, Wan Q. Harnessing the therapeutic value of Tanshinone IIA: a breakthrough therapy in cardiovascular diseases. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1620152
BibTeX
@article{Du2025,
author = {Du, Lanxiang and Guan, Chengyan and Zhang, Hao and Jia, Haoyue and Wan, Qiang},
title = {Harnessing the therapeutic value of Tanshinone IIA: a breakthrough therapy in cardiovascular diseases},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1620152}
}
EUVIMED